Assessing Roche Holding (SWX:ROG) Valuation After New C4 Therapeutics Oncology Partnership [Yahoo! Finance]
C4 Therapeutics, Inc. (CCCC)
NASDAQ:AMEX Investor Relations:
ir.chinacache.com
Company Research
Source: Yahoo! Finance
Roche Holding (SWX:ROG) shares are in focus after C4 Therapeutics announced a new collaboration to develop degrader antibody conjugates for oncology, combining targeted protein degradation with antibody drug conjugation. See our latest analysis for Roche Holding. Roche Holding's share price has softened recently, with a 1 month share price return of 10.47% and a 7 day share price return of 3.04%. However, the 1 year total shareholder return stands at 10.30%, which hints that long term momentum remains more constructive than the short term swings around news like the C4 Therapeutics collaboration. If this kind of oncology partnership has your attention, it may be a good moment to scan for other healthcare names using advanced data tools such as 127 healthcare AI stocks With Roche trading at CHF 322.30, about 13% below the CHF 363.47 analyst target and with some models indicating a larger intrinsic discount, you have to ask: is this a genuine value gap, or is the market already
Show less
Read more
Impact Snapshot
Event Time:
CCCC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CCCC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CCCC alerts
High impacting C4 Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CCCC
News
- C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)GlobeNewswire
- C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple MyelomaGlobeNewswire
- Analysts See Significant Upside in C4 Therapeutics (CCCC) Stock [Yahoo! Finance]Yahoo! Finance
- C4 Therapeutics Details MOMENTUM Phase 2 Start, Eyes Near-Term Decision on EGFR Program at Barclays Confab [Yahoo! Finance]Yahoo! Finance
- C4 Therapeutics, Inc. (CCCC) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]Seeking Alpha
CCCC
Earnings
- 2/26/26 - Beat
CCCC
Sec Filings
- 4/29/26 - Form ARS
- 4/29/26 - Form DEFA14A
- 4/29/26 - Form DEF
- CCCC's page on the SEC website